A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Eligibility criteria
Qualifiers
Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as daunorubicin/anthracycline OR a single monthly cycle of a hypomethylating agent with venetoclax.
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Disqualifiers
Prior allogeneic hematopoietic cell transplantation.
Subjects with active/uncontrolled CNS leukemia. Subjects with prior CNS disease must have no detectable evidence of CSF disease for at least 4 weeks prior to enrollment.
Subjects requiring systemic immunosuppression for any indication are excluded.
New York Heart Association Class II or greater congestive heart failure.
Trial design
Treatments tested in this trial
- Cytokine Induced Memory-Like Natural Killer Cells
- Atezolizumb
- CIML-NK cell therapy
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Genentech, Inc.
Collaborator
Source ClinicalTrials.gov